Skip to main content

Table 4 Tissue and blood miRNA biomarkers for anti-angiogenesis therapeutic response

From: New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications

Clinical Outcomes

miRNAs

Sample type

Detection time

Therapy

Cancer

Patient cohorta

Ref

Better outcomes

miR-378

tissue

post-therapy

bevacizumab

ovarian cancer

113/34

[104]

miR-455-5p

tissue

post-therapy

bevacizumab

mCRC

212/121

[105]

miR-221

tissue

post-therapy

sunitinib

mRCC

30/27

[107]

miR-155, miR-484

tissue

post-therapy

sunitinib

mRCC

16/63

[108]

miR-126

blood

pre- and post-therapy

bevacizumab

mCRC

75/68

[111]

miR-665

blood

pre-therapy

bevacizumab/erlotinib

NSCLC

51/50

[112]

Worse outcomes

miR-664-3p,

tissue

post-therapy

bevacizumab

mCRC

212/121

[105]

miR-425-3p

tissue

pre- and post-therapy

sorafenib

HCC

26/58

[106]

miR-223

blood

pre-therapy

bevacizumab/erlotinib

NSCLC

51/50

[112]

  1. mCRC metastatic colorectal cancer, HCC hepatocellular carcinoma, mRCC metastatic renal cell carcinoma, NSCLC non-small-cell lung cancer
  2. aThe pattern A/B represents patient number in training cohort and validation cohort respectively